Cancer Medicine最新文献

{"title":"Estimating the Burden of False Positives and Implementation Costs From Adding Multiple Single Cancer Tests or a Single Multi-Cancer Test to Standard-Of-Care Screening","authors":"Sarina Madhavan,&nbsp;Allan Hackshaw,&nbsp;Earl Hubbell,&nbsp;Ellen T. Chang,&nbsp;Anuraag Kansal,&nbsp;Christina A. Clarke","doi":"10.1002/cam4.70776","DOIUrl":"https://doi.org/10.1002/cam4.70776","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Blood-based tests present a promising strategy to enhance cancer screening through two distinct approaches. In the traditional paradigm of “one test for one cancer”, single-cancer early detection (SCED) tests a feature high true positive rate (TPR) for individual cancers, but high false-positive rate (FPR). Whereas multi-cancer early detection (MCED) tests simultaneously target multiple cancers with one low FPR, offering a new “one test for multiple cancers” approach. However, comparing these two approaches is inherently non-intuitive. We developed a framework for evaluating and comparing the efficiency and downstream costs of these two blood-based screening approaches at the general population level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We developed two hypothetical screening systems to evaluate the performance efficiency of each blood-based screening approach. The “SCED-10” system featured 10 hypothetical SCED tests, each targeting one cancer type; the “MCED-10” system included a single hypothetical MCED test targeting the same 10 cancer types. We estimated the number of cancers detected, cumulative false positives, and associated costs of obligated testing for positive results for each system over 1 year when added to existing USPSTF-recommended cancer screening for 100,000 US adults aged 50–79.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with MCED-10, SCED-10 detected 1.4× more cancers (412 vs. 298), but had 188× more diagnostic investigations in cancer-free people (93,289 vs. 497), lower efficiency (positive predictive value: 0.44% vs. 38%; number needed to screen: 2062 vs. 334), 3.4× the cost ($329 M vs. $98 M), and 150× higher cumulative burden of false positives per annual round of screening (18 vs. 0.12).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A screening system for average-risk individuals using multiple SCED tests has a higher rate of false positives and associated costs compared with a single MCED test. A set of SCED tests with the same sensitivity as standard-of-care screening detects only modestly more cancers than an MCED test limited to the same set of cancers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Chemotherapy for Post-Menopausal Women With Early Breast Cancer Seems Not to Result in Clinically Significant Changes in Thyroid Function”","authors":"","doi":"10.1002/cam4.70766","DOIUrl":"https://doi.org/10.1002/cam4.70766","url":null,"abstract":"<p>Marina D, Buch-Larsen K, Gillberg L, et al. Chemotherapy for post-menopausal women with early breast cancer seems not to result in clinically significant changes in thyroid function. <i>Cancer Med</i>. 2024; 13:e70015. doi:10.1002/cam4.70015</p><p>The authors have unfortunately identified an error in the <b>Methods section (page 3 of 12)</b>, where we incorrectly described the assay as <b>“immunohistochemistry” instead of the correct term “immunoassay.”</b> The accurate sentence should read “Thyroid parameters (s-TSH, s-TT4, s-FT4, s-TT3) were analyzed by <b>immunoassay</b>; s-TgAb and s-TPOAb were analyzed by immunofluorometry, whereas s-TRAb was analyzed by electrochemiluminescence immunoassay.”</p><p>Additionally, this error appears two times in the <b>Discussion section (page 9 of 12)</b>, where <b>“immunohistochemistry” should also be replaced with “immunoassay.”</b> The accurate sentences should read:</p><p>“Our study group conducted an analysis of thyroid hormones using <b>immunoassay</b>, which was the most affordable assay and readily available at a low cost in our department.”</p><p>“It has been documented that free thyroid hormones measured by LC–MS/MS correlate better with log-transformed TSH than those measured by <b>immunoassay</b>, particularly in certain patient groups.”</p><p>Furthermore, in <b>Supplementary Table S1 (page 3 out of 12)</b>, the assay type for the measurements of TSH, TT4, FT4, and TT3 should be <b>corrected again from “immunohistochemistry” to “immunoassay.”</b> The corrected table can be found in the online Supporting Information.</p><p>We sincerely apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70766","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020","authors":"Laure Vincent,&nbsp;Olivier Decaux,&nbsp;Aurore Perrot,&nbsp;Bruno Royer,&nbsp;Thomas Chalopin,&nbsp;Arthur Bobin,&nbsp;Margaret Macro,&nbsp;Denis Caillot,&nbsp;Lionel Karlin,&nbsp;Caroline Jacquet,&nbsp;Cécile Sonntag,&nbsp;Mohamad Mohty,&nbsp;Laurent Frenzel,&nbsp;Arnaud Jaccard,&nbsp;Salomon Manier,&nbsp;Laurence Sanhes,&nbsp;Driss Chaoui,&nbsp;Philippe Moreau,&nbsp;Ronan Garlantézec,&nbsp;Nathalie Texier,&nbsp;Chanaz Louni,&nbsp;Zakaria Maarouf,&nbsp;Herve Avet Loiseau,&nbsp;Cyrille Hulin,&nbsp;Karim Belhadj Merzoug","doi":"10.1002/cam4.70619","DOIUrl":"https://doi.org/10.1002/cam4.70619","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Background</h3>\u0000 \u0000 <p>Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real-world impacts need to be assessed over the long term.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>EMMY is a non-interventional, prospective dynamic cohort, conducted in France, since 2017, with 900 patients enrolled each year. Newly diagnosed MM (NDMM) who initiated a treatment from 2017 to 2020 are here described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1036 non-transplant eligible (NTE) patients (median age: 74.9 years) and 561 patients who received autologous stem cell transplantation (ASCT) (median age: 60.6 years) were enrolled. For ASCT patients, a shift in induction treatment from bortezomib-thalidomide-dexamethasone (VTd) (29.1%) to bortezomib-lenalidomide-dexamethasone (VRd) (55.1%) marked the period. Maintenance treatment with R after ASCT became a standard (75% of patients). In NTE patients, R-based regimens were increasingly used from 29.4% in 2017 (of whom Rd.: 17.0%, VRd: 10.6%) to 73.3% in 2020 (of whom Rd.: 21.8%, VRd: 48.5%). Median progression-free survival (mPFS) was 46.5 months (95% CI: 37.8–50.6) and 18.7 months (95% CI: 16.3–20.8) in ASCT and NTE patients, respectively. In the ASCT group, patients treated with and without R maintenance had a mPFS of 51.8 (95% CI: 44.1–NA) and 29.6 months (95% CI: 21.8–40.9), respectively. In the NTE group, the mPFS was 26.3 (95% CI: 21.9–30.9) and 14.6 months (95% CI: 11.9–17.7) in patients who received an R-based and non-R-based regimen, respectively. The estimated 48-month overall survival rates were 89% (95% CI: 84.5–92.2) and 63% (95% CI: 58.5–67.1) for ASCT and NTE patients, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The 2017–2020 period was marked by the expansion of R use in both NDMM ASCT and NTE patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades","authors":"Zerubbabel K. Asfaw,&nbsp;Tirone Young,&nbsp;Cole Brown,&nbsp;Mehek Dehdia,&nbsp;Lily Huo,&nbsp;Kunal K. Sindhu,&nbsp;Stanislav Lazarev,&nbsp;Robert Samstein,&nbsp;Sheryl Green,&nbsp;Isabelle M. Germano","doi":"10.1002/cam4.70673","DOIUrl":"https://doi.org/10.1002/cam4.70673","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (<i>p</i> = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, <i>p</i> = 0.012), higher median citations (30 vs. 19, <i>p</i> &lt; 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, <i>p</i> &lt; 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (<i>p</i> &lt; 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70673","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of Four Serum Biomarkers With Optimal Diagnostic and Prognostic Potential for Gastric Cancer Based on Machine Learning Algorithms","authors":"Yi Liu,&nbsp;Bingxian Bian,&nbsp;Shiyu Chen,&nbsp;Bingqian Zhou,&nbsp;Peng Zhang,&nbsp;Lisong Shen,&nbsp;Hui Chen","doi":"10.1002/cam4.70659","DOIUrl":"https://doi.org/10.1002/cam4.70659","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gastric cancer (GC) is considered a highly heterogeneous disease, and currently, a comprehensive approach encompassing molecular data from various biological levels is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study conducted different analyses, including the identification of differentially expressed genes (DEGs), weighted correlation networks (WGCNA), single-cell RNA sequencing (scRNA-seq), mRNA expression-based stemness index (mRNAsi), and multiCox analysis, utilizing data from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Subsequently, the machine learning algorithms including least absolute shrinkage and selection operator (LASSO) regression and random forest (RF), combined with multiCox analysis were exploited to identify hub genes. These findings were then validated through the receiver operating characteristic (ROC) curve and Kaplan–Meier analysis, and were experimentally confirmed in GC samples by reverse transcription–polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Integrated analysis of TCGA and GEO databases, coupled with LASSO regression and RF algorithms, allowed us to identify 18 hub genes encoding differentially expressed secreted proteins in GC. The results of RT-PCR and bioinformatics analysis revealed four promising biomarkers with optimal diagnostic and prognostic potential. ROC analysis and Kaplan–Meier curves highlighted CHI3L1, FCGBP, VSIG2, and TFF2 as promising biomarkers for GC, offering superior modeling accuracy. These findings were further confirmed by RT-PCR and ELISA, affirming the clinical utility of these four biomarkers. Additionally, CIBERSORT analysis indicated a potential correlation between the four biomarkers and the infiltration of B memory cells and Treg cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study unveiled four promising biomarkers present in the serum of patients with GC, which could serve as powerful indicators of GC and provide valuable insights for further research into GC pathogenesis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143612477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic Changes Associated With Endogenous FBXW7 Mutations in Moderately Differentiated Endometrial Cancer Cells Include Increased TROP2 and Galectin-3 Levels","authors":"Mary Ellen Urick,&nbsp;Suresh Kumar Chalapareddy,&nbsp;Eun-Jeong Yu,&nbsp;Daphne W. Bell","doi":"10.1002/cam4.70765","DOIUrl":"https://doi.org/10.1002/cam4.70765","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Endometrial cancer (EC) is the fourth most commonly diagnosed cancer among women in the US and the fifth leading cause of cancer death in this population. The <i>FBXW7</i> tumor suppressor gene is frequently mutated in all molecular subtypes of EC. The encoded protein is part of a ubiquitin ligase complex that targets substrate proteins for ubiquitination and, in most instances, proteasome-mediated degradation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The purpose of this investigation was to identify the proteomic changes associated with endogenous <i>FBXW7</i> mutations in EC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials &amp; Methods</h3>\u0000 \u0000 <p>Quantitative LC–MS/MS was used to identify significant (<i>p</i> &lt; 0.05) differences in the proteomes and phosphoproteomes of two <i>FBXW7</i>-mutated EC cell lines, HEC-1-B^{FBXW7−R367X} and JHUEM-1^{FBXW7−R505C}, as compared to isogenic mutation-corrected cell lines. Western blotting was performed to orthogonally validate a subset of protein changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analysis of LC–MS/MS results identified 397 total proteins and/or phosphoproteins with significantly different levels in both HEC-1-B^{FBXW7−R367X} and JHUEM-1^{FBXW7−R505C}, as compared to isogenic mutation-corrected cell lines. This protein set included increased levels of TROP2, galectin-3, ASS1, and PLCG2 in both HEC-1-B^{FBXW7−R367X} and JHUEM-1^{FBXW7−R505C} cells; these perturbations orthogonally validated by western blotting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides novel insights into the proteomic and phosphoproteomic effects of the endogenous FBXW7^−R367X and FBXW7^−R505C mutations in EC cells, including increased levels of galectin-3, a potentially druggable target, and of TROP2, which is a druggable target in EC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70765","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “The Treatment of Primary Lymphoepithelioma-Like Carcinoma in the Head and Neck and Nasopharyngeal Carcinoma”","authors":"","doi":"10.1002/cam4.70751","DOIUrl":"https://doi.org/10.1002/cam4.70751","url":null,"abstract":"<p>Lin Q, Du M, Yan S, Zhang X, Li X, Zhang Y, Zhang S, Chen S, Song M. The Treatment of Primary Lymphoepithelioma-Like Carcinoma in the Head and Neck and Nasopharyngeal Carcinoma. <i>Cancer Med</i>. 2024 Nov;13(22):e70389. doi: 10.1002/cam4.70389</p><p>The article category has been changed from “Review” to “Research Article.”</p><p>We apologize for this error.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing and Implementing a Colorectal Cancer Screening Program in Uganda: Stakeholder Perceived Barriers and Opportunities","authors":"Nicholas Matovu,&nbsp;Helen G. Coleman,&nbsp;Gerald Mutungi,&nbsp;Michael Donnelly,&nbsp;Lynne Lohfeld,&nbsp;Brian T. Johnston,&nbsp;Maurice B. Loughrey,&nbsp;Noleb M. Mugisha,&nbsp;Charlene M. McShane","doi":"10.1002/cam4.70662","DOIUrl":"https://doi.org/10.1002/cam4.70662","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Colorectal cancer (CRC) incidence is increasing in Uganda. Despite this, and the disproportionately high burden of early onset and late-stage CRC cases, no CRC screening program exists in Uganda. To guide and inform future CRC prevention efforts, interviews with key stakeholders were undertaken to better understand the perceived barriers and opportunities relevant to the development and implementation of a CRC screening program in Uganda.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Semi-structured key informant interviews were conducted with key stakeholders in cancer prevention, screening and policy/programming (<i>n</i> = 11, 6 medically qualified and 5 non-medical), who were recruited across Uganda using maximum variation sampling between March and April 2022. Interviews were audio recorded, transcribed, coded and later analysed using a deductive thematic analysis approach guided by the social ecological model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Major barriers included lack of government priority for CRC prevention programs, lack of resources/funding for CRC screening (policy level), inadequate screening facilities and equipment, limited training/knowledge of CRC and capacity of the health workforce (health system level), challenges in the delivery of CRC awareness messages (community level), emotions associated with CRC screening and poor awareness of CRC and its symptoms (individual level). Major opportunities included the existence of a draft national cancer control plan (policy level), existence of less costly CRC screening alternatives, less costly primary prevention measures (health system level), existence of community leadership and structures (community level), likely acceptability of the faecal occult blood test and peer support (individual level).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There are substantive barriers to CRC screening program development and implementation in Uganda. However, there are signs, like the development of a cancer control plan, that suggest a shift towards strategic planning and allocation of resources at a population level for addressing the issues of cancer prevention and care, including CRC. In the meantime, efforts should prioritise primary prevention interventions such as mass education to promote CRC awareness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70662","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Activity of Biomarkers Associated With Metastasis in Osteosarcoma Cell Lines","authors":"Nidia Ednita Beltrán-Hernández,&nbsp;Luis Cardenas,&nbsp;Verónica Jimenez-Jacinto,&nbsp;Leticia Vega-Alvarado,&nbsp;Heriberto Manuel Rivera","doi":"10.1002/cam4.70391","DOIUrl":"https://doi.org/10.1002/cam4.70391","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Osteosarcoma, a highly aggressive bone cancer primarily affecting children and young adults, remains a significant challenge in clinical oncology. Metastasis stands as the primary cause of mortality in osteosarcoma patients. However, the mechanisms driving this process remain incompletely understood. Clarifying the molecular pathways involved in metastasis is essential for enhancing patient prognoses and facilitating the development of targeted therapeutic strategies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;RNA sequencing (RNA-Seq) analysis was employed to compare three conditions, hFOB1.19 versus Saos-2, hFOB1.19 versus SJSA-1, and Saos-2 versus SJSA-1, involving non-cancer osteoblasts (hFOB1.19) and highly metastatic osteosarcoma cell lines (Saos-2 and SJSA-1). Additionally, ENA datasets of RNA-Seq from osteosarcoma biopsies were included. Differentially expressed genes (DEGs) were identified and analyzed through enrichment pathway analysis and protein–protein interaction (PPI) networks. Additionally, for gene candidates, a biochemical evaluation was performed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;DEGs associated with biological functions pertinent to migration, invasion, and metastasis in osteosarcoma were identified. Notably, matrix metalloproteinase-2 (MMP-2) emerged as a promising candidate. Both canonical or full-length (FL-&lt;i&gt;mmp-2&lt;/i&gt;) and N-terminal truncated (NTT-&lt;i&gt;mmp-2&lt;/i&gt;) isoforms were discerned in biopsies. Moreover, MMP-2's activity was characterized in cell lines. Additionally, mRNA expression of voltage-gated sodium channels (Na&lt;sub&gt;V&lt;/sub&gt;s) and voltage-gated potassium channels (K&lt;sub&gt;V&lt;/sub&gt;s) was detected, and their functional expression was validated using patch clamp techniques. Evaluation of cell line migration and invasion capacities revealed their reduction in the presence of ion channel blockers (TTX and TEA) and MMP inhibitor (GM6001).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The gene functional enrichment analysis of DEGs enabled the identification of interaction networks in osteosarcoma, thereby revealing potential biomarkers. Moreover, the elucidated co-participation of TTX-sensitive Na&lt;sub&gt;V&lt;/sub&gt;s and MMP-2 in facilitating migration and invasion suggests their suitability as novel prognostic biomarkers for osteosarcoma. Additionally, this study introduces a model delineating the potential interaction mechanism among ion channels, MMP-2, and other crucial factors in the metastatic cascade of osteosarcoma.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 &lt;/d","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Trends in Distress Among Cancer Patients: A Systematic Review and Meta-Analysis","authors":"Dana G. Rowe,&nbsp;Ellen O'Callaghan,&nbsp;Seeley Yoo,&nbsp;Juliet C. Dalton,&nbsp;Joshua Woo,&nbsp;Edwin Owolo,&nbsp;Tara Dalton,&nbsp;Margaret O. Johnson,&nbsp;Andrea N. Goodwin,&nbsp;Kerri-Anne Crowell,&nbsp;Samantha Kaplan,&nbsp;Melissa M. Erickson,&nbsp;C. Rory Goodwin","doi":"10.1002/cam4.70456","DOIUrl":"https://doi.org/10.1002/cam4.70456","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Distress is common among cancer patients, especially those undergoing surgery. However, no study has systematically analyzed distress trends in this population. The purpose of this study was to systematically review perioperative rates of distress, as well as differences across cancer types, in cancer patients undergoing surgical intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review was conducted using PubMed, EMBASE, Scopus, and APA PsycINFO (searched until July 17, 2023). Included studies were clinical studies of cancer patients undergoing surgery reporting distress measured by the National Comprehensive Cancer Network (NCCN) distress thermometer (DT). Data on study and patient characteristics, and preoperative and postoperative distress rates were extracted. Results were pooled, and overall distress rates were calculated as weighted means. Subanalysis by cancer type was performed. Three meta-analyses were conducted: (1) preoperative distress, (2) postoperative distress, and (3) change in distress.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-seven studies including 13,410 cancer patients were reviewed. Most patients were female (67.4%), White (77.8%), and married/partnered (72.2%), with an average age of 59.2 years. The most common cancers were breast (14 studies), brain (8), and colorectal (7). Weighted mean pre- and postoperative distress scores were 5.1 and 4.5, respectively. Distress remained high through 30 days postoperatively, then declined thereafter. Brain cancer patients reported the highest postoperative distress (5.1), followed by breast cancer patients (4.9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The perioperative phase is a critical period of elevated distress in cancer patients. Preoperatively, patients experience moderate to severe levels of distress, which persist throughout the early postoperative phase, gradually declining from the 1-month postoperative mark onwards.</p>\u0000 </section>\u0000 </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70456","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}